Literature DB >> 31576342

New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?

Markus Eckstein1, Shilpa Gupta2.   

Abstract

Entities:  

Year:  2019        PMID： 31576342      PMCID： PMC6685893          DOI： 10.21037/atm.2019.06.12

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  36 in total

1.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

2.  T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Authors:  Patrick A Ott; Yung-Jue Bang; Sarina A Piha-Paul; Albiruni R Abdul Razak; Jaafar Bennouna; Jean-Charles Soria; Hope S Rugo; Roger B Cohen; Bert H O'Neil; Janice M Mehnert; Juanita Lopez; Toshihiko Doi; Emilie M J van Brummelen; Razvan Cristescu; Ping Yang; Kenneth Emancipator; Karen Stein; Mark Ayers; Andrew K Joe; Jared K Lunceford
Journal:  J Clin Oncol       Date:  2018-12-13       Impact factor: 44.544

3.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Authors:  Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan
Journal:  J Clin Invest       Date:  2017-06-26       Impact factor: 14.808

4.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

7.  Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Authors:  Andreas H Scheel; Gudrun Baenfer; Gustavo Baretton; Manfred Dietel; Rolf Diezko; Thomas Henkel; Lukas C Heukamp; Bharat Jasani; Korinna Jöhrens; Thomas Kirchner; Felix Lasitschka; Iver Petersen; Simone Reu; Hans-Ulrich Schildhaus; Peter Schirmacher; Kristina Schwamborn; Ulrich Sommer; Oliver Stoss; Markus Tiemann; Arne Warth; Wilko Weichert; Jürgen Wolf; Reinhard Büttner; Josef Rüschoff
Journal:  Histopathology       Date:  2017-11-21       Impact factor: 5.087

8.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud
Journal:  Lancet       Date:  2017-12-18       Impact factor: 79.321

9.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

10.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).

Authors:  Patrick Danaher; Sarah Warren; Rongze Lu; Josue Samayoa; Amy Sullivan; Irena Pekker; Brett Wallden; Francesco M Marincola; Alessandra Cesano
Journal:  J Immunother Cancer       Date:  2018-06-22       Impact factor: 13.751
View more
  3 in total

1.  Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway.

Authors:  Hao Peng; Rong Xue; Zheng Ju; Jiannan Qiu; Jiawei Wang; Wei Yan; Xiaojie Gan; Yizhu Tian; Hongbin Shen; Xiaoming Wang; Xuehao Wang; Xuhao Ni; Yue Yu; Ling Lu
Journal:  Ann Transl Med       Date:  2020-07

Review 2.  Role of the tumor immune microenvironment in tumor immunotherapy.

Authors:  Changsheng Zhou; Qianqian Liu; Yi Xiang; Xin Gou; Wengang Li
Journal:  Oncol Lett       Date:  2021-12-20       Impact factor: 2.967

3.  Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy.

Authors:  Ji Wang; Chao Chen; Lu Wang; Mingjun Xie; Xinyang Ge; Sufan Wu; Yong He; Xiaozhou Mou; Chenyang Ye; Yi Sun
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.